Literature DB >> 25188733

The psychopharmacology algorithm project at the Harvard South Shore Program: an algorithm for acute mania.

Othman Mohammad1, David N Osser.   

Abstract

This new algorithm for the pharmacotherapy of acute mania was developed by the Psychopharmacology Algorithm Project at the Harvard South Shore Program. The authors conducted a literature search in PubMed and reviewed key studies, other algorithms and guidelines, and their references. Treatments were prioritized considering three main considerations: (1) effectiveness in treating the current episode, (2) preventing potential relapses to depression, and (3) minimizing side effects over the short and long term. The algorithm presupposes that clinicians have made an accurate diagnosis, decided how to manage contributing medical causes (including substance misuse), discontinued antidepressants, and considered the patient's childbearing potential. We propose different algorithms for mixed and nonmixed mania. Patients with mixed mania may be treated first with a second-generation antipsychotic, of which the first choice is quetiapine because of its greater efficacy for depressive symptoms and episodes in bipolar disorder. Valproate and then either lithium or carbamazepine may be added. For nonmixed mania, lithium is the first-line recommendation. A second-generation antipsychotic can be added. Again, quetiapine is favored, but if quetiapine is unacceptable, risperidone is the next choice. Olanzapine is not considered a first-line treatment due to its long-term side effects, but it could be second-line. If the patient, whether mixed or nonmixed, is still refractory to the above medications, then depending on what has already been tried, consider carbamazepine, haloperidol, olanzapine, risperidone, and valproate first tier; aripiprazole, asenapine, and ziprasidone second tier; and clozapine third tier (because of its weaker evidence base and greater side effects). Electroconvulsive therapy may be considered at any point in the algorithm if the patient has a history of positive response or is intolerant of medications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25188733     DOI: 10.1097/HRP.0000000000000018

Source DB:  PubMed          Journal:  Harv Rev Psychiatry        ISSN: 1067-3229            Impact factor:   3.732


  6 in total

Review 1.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

2.  Diagnosis and Treatment of Bipolar Illness in the Primary Care Office.

Authors:  Jay A Brieler; Elizabeth Keegan-Garrett
Journal:  Mo Med       Date:  2022 May-Jun

3.  Changing Trends in Treatment of Acute Mania: Experience of a Tertiary Centre Over a Decade.

Authors:  Mehmet Kemal Arıkan; Cana Aksoy Poyraz; Alper Baş; N Gamze Usta Sağlam; Gizem Cetiner Batun; Gözde Gültekin; Burç Çağrı Poyraz
Journal:  Psychiatr Q       Date:  2016-06

4.  Low-Dose Lithium Stabilizes Human Endothelial Barrier by Decreasing MLC Phosphorylation and Universally Augments Cholinergic Vasorelaxation Capacity in a Direct Manner.

Authors:  Bert Bosche; Marek Molcanyi; Soham Rej; Thorsten R Doeppner; Mark Obermann; Daniel J Müller; Anupam Das; Jürgen Hescheler; R Loch Macdonald; Thomas Noll; Frauke V Härtel
Journal:  Front Physiol       Date:  2016-12-06       Impact factor: 4.566

5.  Effectiveness of clozapine, oxcarbazepine and rivastigmine combination in a bipolar disorder patient with initial cerebral atrophy.

Authors:  Paolo Morana; Federico Mucci; Stefano Baroni; Alessandra Della Vecchia; Armando Piccinni; Benedetto Morana; Donatella Marazziti
Journal:  Clin Case Rep       Date:  2020-01-07

Review 6.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: The Clinical Guidelines.

Authors:  Konstantinos N Fountoulakis; Heinz Grunze; Eduard Vieta; Allan Young; Lakshmi Yatham; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.